NEW YORK, April 11 – The University of Geneva has licensed a key DNA-binding technology to Gene Soft, a South San Francisco, Calif.-based biotechnology company that is developing small molecule DNA sequence specific drugs, the organizations said Wednesday.

This technology, developed by Ulrich Laemmi, a professor of molecular biology at the University of Geneva, involves DNA-binding molecules that act to change the structure of chromatin, the complex formed by DNA and the proteins to make chromosomes.